Primeros resultados de la caracterización del contenido estomacal de juveniles 0+ de atún rojo Thunnus thynnus

Stomach contents from 19 dead young bluefin tuna were analyzed in the framework of the SELFDOTT project (From capture based to SELF-sustained aquaculture and Domestication Of bluefin tuna, Thunnus thynnus). The fish were captured close to Cartagena (Murcia- Spain) between the 3rd and the 16th of October 2008, using the «curricán» method (a Spanish term meaning to fish by trailing a baited line along behind a boat). The first stomach analyses show that cephalopods are the main prey (53% in weight 49% in number), followed by fishes (28%, 24%) and crustaceans (2%, 27%). The main prey species is the squid Illex coindetti.Proyecto SELFDOT

Aspirin Compared to Low Intensity Anticoagulation in Patients with Non-Valvular Atrial Fibrillation. A Systematic Review and Meta-Analysis.

Despite its lack of efficacy, aspirin is commonly used for stroke prevention in atrial fibrillation. Since prior studies have suggested a benefit of low-intensity anticoagulation over aspirin in the prevention of vascular events, the aim of this systematic review was to compare the outcomes of patients with non-valvular atrial fibrillation treated with low-intensity anticoagulation with Vitamin K antagonists or aspirin.We conducted a systematic review searching Ovid MEDLINE, Embase and the Cochrane Central Register of Controlled Trials, from 1946 to October 14th, 2015. Randomized controlled trials were included if they reported the outcomes of patients with non-valvular atrial fibrillation treated with a low-intensity anticoagulation compared to patients treated with aspirin. The primary outcome was a combination of ischemic stroke or systemic embolism. The random-effects model odds ratio was used as the outcome measure.Our initial search identified 6309relevant articles of which three satisfied our inclusion criteria and were included. Compared to low-intensity anticoagulation, aspirin alone did not reduce the incidence of ischemic stroke or systemic embolism OR 0.94 (95% CI 0.57-1.56), major bleeding OR 1.06 (95% CI 0.42-2.62) or vascular death OR 1.04 (95% CI 0.61-1.75). The use of aspirin was associated with a significant increase in all-cause mortality OR 1.66 (95% CI 1.12-2.48).In patients with non-valvular atrial fibrillation, aspirin provides no benefits over low-intensity anticoagulation. Furthermore, the use of aspirin appears to be associated with an increased risk in all-cause mortality. Our study provides more evidence against the use aspirin in patients with non-valvular atrial fibrillation

All cause mortality meta-analysis.

<p>The addition of a study arm from the AFASAK study [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0142222#pone.0142222.ref013" target="_blank">13</a>] comparing aspirin vs. low-intensity anticoagulation plus aspirin did not modify any of the estimates including the reduction in all-cause mortality [OR 1.66(95% CI 1.15–2.38); I² 0%]. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0142222#pone.0142222.t003" target="_blank">Table 3</a> presents a summary of the number of individual events from each study.</p

Quality assessment.

<p>AFASAK: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation; PATAF: Primary Prevention of Arterial Thromboembolism in patients with Non-rheumatic Atrial Fibrillation in Primary Care</p><p>Quality assessment.</p

Meta-analysis of ischemic stroke or systemic embolism.

<p>There was no difference in the rate of major bleeding [OR 1.06 (95% CI 0.42–2.62); I² 0%] or vascular death [OR 1.04 (95% CI 0.61–1.75); I² 1%] but patients treated with aspirin had an increased risk in all-cause mortality [OR 1.66 (95% CI 1.12–2.48); I² 0%] (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0142222#pone.0142222.g003" target="_blank">Fig 3</a>). The difference in all-cause mortality was driven by an increased risk in non-vascular death in patients treated with aspirin [OR 3.20(95% CI 1.31–7.82); I² 0%], whereas the risk for death from unknown causes not significantly different [OR 1.525 (95% CI 0.65–3.55; I² 0%]. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0142222#pone.0142222.t004" target="_blank">Table 4</a> provides the number of events in each study.</p

Characteristics of the studies included in the main analysis.

<p>AFASAK: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation;</p><p>PATAF: Primary Prevention of Arterial Thromboembolism in patients with Non-rheumatic Atrial Fibrillation in Primary Care;</p><p>HTN: Hypertension; DBT: Diabetes; HF: Heart Failure; TTR: Time in therapeutic range</p><p>Characteristics of the studies included in the main analysis.</p

Current recommendation for the use of aspirin in patients with non-valvular atrial fibrillation.

<p>OAC: Oral anticoagulation; AF: Atrial Fibrillation</p><p>Current recommendation for the use of aspirin in patients with non-valvular atrial fibrillation.</p

Prevalence and Geographical Variation of Prothrombin G20210A Mutation in Patients with Cerebral Vein Thrombosis: A Systematic Review and Meta-Analysis

<div><p>Objectives</p><p>To compare the prevalence of prothrombin G20210A in patients with objectively confirmed cerebral vein or cortical vein thrombosis against healthy controls, and evaluate geographical variations.</p><p>Design</p><p>Systematic review and meta-analysis of case control studies.</p><p>Methods</p><p>We conducted a systematic review of electronic databases including MEDLINE and EMBASE. The main outcome was the prevalence of prothrombin G20210A in patients with objectively confirmed cerebral vein or cortical vein thrombosis; we also analyzed individual country variations in the prevalence. The random-effects model OR was used as the primary outcome measure.</p><p>Results</p><p>In total 19 studies evaluated 868 cases of cerebral venous thrombosis and 3981 controls. Prothrombin G20210A was found in 103/868 of the patients with cerebral venous thrombosis and 105/3999 of the healthy controls [random effects pooled OR 5.838, 95% CI 3.96 to 8.58; I²17.9%]. The prevalence of prothrombin G20210A was significantly elevated in Italian studies (OR 9.69), in Brazilian studies (OR 7.02), and in German studies (OR 3.77), but not in Iranian studies (OR 0.98).</p><p>Conclusion</p><p>Prothrombin G20210A is significantly associated with cerebral venous thrombosis when compared to healthy controls, although this association is highly dependent on the country of origin.</p></div

Flow diagram.

<p>Flow diagram.</p